News | April 06, 2015

Hot Flashes at Younger Age May Signal Greater Cardiovascular Risk

Study is first to look at device-validated hot flashes in relation to endothelial function

hot flashes, endothelial function, cardiovascular disease, risk, women, age

April 6, 2015 — Two new studies suggest women who experience hot flashes earlier in life appear to have poorer endothelial function — one of the earliest signs of cardiovascular disease— than those who have hot flashes later in life or not at all. Both studies were presented at the American College of Cardiology’s 64th Annual Scientific Session in San Diego.

“We tend to think of hot flashes as solely a quality of life issue, but these studies — based on data from two very different samples — call that into question,” said Rebecca C. Thurston, Ph.D., associate professor of psychiatry, psychology and epidemiology, University of Pittsburgh, and lead author of both studies. “Hot flashes appear to be more toxic in younger than older women.”

The research suggests early onset hot flashes may serve as a red flag to help identify women at greater cardiovascular risk who could benefit from more aggressive risk reduction early in midlife, Thurston said.

The studies — funded by the National Heart, Lung, and Blood Institute — add to emerging research linking hot flashes with cardiovascular risk, and endothelial dysfunction in particular.

In the first of the two studies, researchers enrolled 189 healthy peri- or post-menopausal women and examined the relationship between hot flashes and flow-mediated dilation, a marker of endothelial function that tests how well the vessels dilate in response to sheer stress on the vessel wall. Unlike similar studies that have relied solely on women self-reporting hot flashes, women in this study wore a monitor for 24 hours to confirm and quantify hot flashes. Flow-mediated dilation was assessed through a noninvasive ultrasound of the brachial artery in the forearm, which Thurston said correlates well with responses in the coronary artery.

More hot flashes over a 24-hour period were associated with significantly lower flow-mediated dilation and, therefore, poorer endothelial function in younger women, defined in this study as age 52 and younger. Hot flashes were not related to the early indicator of heart disease in the older women. The findings remained significant even after controlling for age, race, previous hormone use, menopausal stage and body mass index.

It seems the number of hot flashes matters too. On average, women in the study had nine hot flashes in the 24-hour period in which they were monitored. Having any number of hot flashes at a younger age was related to a 3 percent reduction in flow-mediated dilation compared to the younger women with no symptoms, which Thurston said is clinically significant. In particular, flow-mediated dilation in younger women who had 10 or more hot flashes a day was reduced by almost half compared to younger women without hot flashes, indicating the more hot flashes these women had, the more evidence of endothelial dysfunction.

“Endothelial function is very important to vascular health, and it’s often the first thing to go in the atherosclerotic process, so it’s an early marker of cardiovascular risk,” Thurston said. The endothelium is a thin membrane that lines the inside of the heart and blood vessels. It helps regulate blood clotting, immune function, inflammation and new blood vessel formation. Poor endothelial function is known to play a role in the development of coronary artery disease and other diseases of the arteries.

The second study further validates the findings, but in older women who already had signs of heart disease and were not on hormone therapy. Researchers evaluated 104 post-menopausal women with an average age of 67 who were enrolled in the Women’s Ischemic Syndrome Evaluation study, which was designed to gain a better understanding of female-specific patterns of developing cardiovascular disease.

Hot flashes were assessed by questionnaire and women were grouped based on when they recall having hot flashes: never, early onset (age 42 or younger) or traditional onset (after age 42). Women who had early onset hot flashes had significantly lower flow-mediated dilation suggesting poorer endothelial function compared with women whose symptoms started later. This finding remained significant even after controlling for age, race, prior hormone use and obstructive coronary disease. There was no difference in flow-mediated dilation between women who never had hot flashes and those who first experienced them after age 42.

“Hot flashes occur at a time in a woman’s life when her risk for heart disease increases,” Thurston said. “Because current cardiovascular risk algorithms do not always predict clinical cardiovascular disease well for midlife women, gaining a better understanding of the role vasomotor symptoms might play on vascular health could help identify women most at risk.”

Previous studies have been mixed, although several have also linked hot flashes to lower flow-mediated dilation. Still, more research is needed to refine the precise age at which hot flashes seem to be most associated with worse endothelial dysfunction and to investigate whether the severity of hot flashes plays a role. Research is also needed to uncover the shared mechanisms that might be underlying hot flashes and endothelial function.

These studies are limited due to relatively small sample sizes and the use of a surrogate measure for early cardiovascular disease. Research to investigate the association of hot flashes with cardiovascular events and other subclinical markers is needed.

For more information: www.acc.org

Related Content

New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
Overlay Init